secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001599298-24-000087
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics Q1 net loss $43.5M; cash $157M; ivonescimab shows 34% intracranial response in NSCLC brain mets
--------------------------------------------------------------------------------

- GAAP net loss $43.5M ($0.06/sh) vs $542.3M ($1.43/sh) prior year; non-GAAP net loss $34.0M ($0.05/sh).
- Cash and investments $157M at March 31; operating cash outflow $30.1M; guidance cash runway through Q1 2025.
- R&D expenses $30.9M GAAP, up from $9.9M; non-GAAP R&D $28.5M as trial enrollment expands.
- Ivonescimab Phase II data: 34% intracranial response rate; median intracranial PFS 19.3 months in NSCLC brain metastases; mPFS 11.1 months in first-line squamous NSCLC.
- HARMONi (EGFR-mutant NSCLC) enrollment completion expected H2 2024; HARMONi-3 (first-line squamous) first patient treated Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000087/0001599298-24-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000087/smmt-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer